Peripheral neurotoxicity due to albumin paclitaxel
Conditions
Interventions
One:Oral herbal group alone
Two:Bloodletting group alone
Four:Blank control group
Three:Chinese medicine combined with four end bloodletting groups
Sponsors
Shanxi Institute of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: ?Patients who have pathologically or cytologically confirmed lung cancer or breast cancer. ?Patients' age 18-80 years, regardless of gender. ?Patients with a KPS score = 60 and an expected survival of not less than 3 months. ?Patients who have developed peripheral neurotoxicity after receiving albumin paclitaxel treatment. ? no major visceral organ dysfunction and no cardiovascular or cerebrovascular complications. ? Skin of all four limbs is intact. ? Those who can understand the situation of this study, voluntarily accept the TCM treatment and voluntarily accept the questionnaire for good compliance.
Exclusion criteria
Exclusion criteria: ?Patients with reduced platelets prone to bleeding. ?Those who do not meet the above inclusion criteria. ?Patients who have symptoms related to nerve compression due to brain metastases or who have peripheral nerve damage due to tumour compression. ?Patients with other previous peripheral neuropathies, e.g. neurological diseases, orthopaedic related diseases, peripheral neuropathies due to circulatory disorders. ? those with a history of allergy to drug exposure or the presence of skin lesions on the hands and feet (e.g. eczema). ? Those who are unable to cooperate with treatment. ?Women during pregnancy or breastfeeding. ?Those currently or within 4 weeks participating in other clinical trials. ?Allergic individuals who are susceptible to hypersensitivity to the drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| EORTC QLQ-CIPN20 Neurotoxicity Evaluation Criteria; | — |
Secondary
| Measure | Time frame |
|---|---|
| Peripheral neurotoxicity symptom score;Electromyography;WHO classification of antineoplastic drugs for peripheral neurotoxicity;NCI-CTCAE5.0 Peripheral Neurotoxicity Classification; | — |
Countries
China
Contacts
Public ContactLi Xiaoli
Shanxi Provincial Hospital of Traditional Chinese Medicine
Outcome results
None listed